White Paper
Our Perspectives on the US FDA Patient-Focused Drug Development (PFDD) Guidance 1 and 2
Generating robust data to understand patients' experiences with disease and its treatment
Hillary Whittaker
Sep 25, 2020
Download

The FDA is currently developing a series of four Patient-Focused Drug Development (PFDD) Guidance Documents for the healthcare industry. This insight brief outlines PFDD Guidance 1 and 2, which are focused on ensuring that sponsors obtain robust, meaningful and interpretable patient input to understand their experience with their disease and its treatment to inform medical product development.

Related solutions

Contact Us